Cerebrolysin Protected Against Cell Death in Only 30% of Patients with a Rare Hereditary Brain Disease | Research

The takeaway

The neuroprotective peptide drug cerebrolysin reduced oxidative stress-induced cell death in lymphocytes from only 5 out of 15 CADASIL patients, suggesting its anti-apoptotic effects may be limited by the underlying genetic mutation.

30%
of CADASIL patients showed a protective response to cerebrolysin against oxidative stress-induced cell death

What the researchers found

When cerebrolysin was added to lymphocytes from CADASIL patients cultured under normal conditions, it had no effect on cell death rates. However, when cells were stressed with the pro-apoptotic agent 2-deoxy-D-ribose (dRib), cerebrolysin significantly decreased apoptosis after 48 hours — but only in 5 out of 15 patients (33%).

In the remaining 10 patients, cerebrolysin showed no protective effect against oxidative stress-induced cell death. The authors concluded that the Notch3 gene mutation in CADASIL probably does not influence cerebrolysin's anti-apoptotic properties, and that the variable response may reflect individual differences in disease biology.

Why it matters

CADASIL is a devastating hereditary condition that causes strokes and dementia, and there are currently no disease-modifying treatments. Understanding whether neuroprotective peptide drugs like cerebrolysin could help these patients is an important research question, even if this early in-vitro study found limited effectiveness.

How the study worked

The researchers collected peripheral blood lymphocytes from 15 CADASIL patients (ages 34–70). They cultured these cells in the lab and exposed them to 2-deoxy-D-ribose, a sugar that triggers oxidative stress and cell death. Cerebrolysin was then added to see if it could prevent the cells from dying. Cell death was measured using flow cytometry and fluorescence microscopy after 48 hours of culture.

What this study cannot tell us

This was an in vitro study using blood cells in a lab dish, not brain tissue, so results may not reflect what happens in the brain. The sample size of 15 patients is very small. The study only measured one type of stress (oxidative) and one time point (48 hours). There was no explanation for why 30% of patients responded while 70% did not, beyond speculation about the Notch3 gene.

How to read the evidence

This is a small in vitro laboratory study using blood cells from 15 patients. While it provides mechanistic insights, it cannot demonstrate clinical effectiveness and sits at the lower end of the evidence hierarchy.

When this study was published

Published in 2013, this study is over a decade old. Cerebrolysin research has continued, but no major breakthroughs for CADASIL treatment have emerged since, making this still representative of the state of knowledge.

The bigger picture

Cerebrolysin has shown neuroprotective effects in stroke and dementia research, but this study suggests those benefits may not extend uniformly to genetic conditions like CADASIL. The variable response among patients highlights how genetic background can influence drug effectiveness and underscores the challenge of finding treatments for rare hereditary neurological diseases.

Questions still open

What distinguishes the 30% of CADASIL patients who responded to cerebrolysin from those who did not?
Would cerebrolysin show different results in actual brain tissue or neurons from CADASIL patients?
Could combination therapy with cerebrolysin and other neuroprotective agents improve outcomes in CADASIL?

Common questions

What is CADASIL and why is it hard to treat?

CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is a rare inherited condition caused by mutations in the Notch3 gene. It causes recurring strokes, progressive dementia, and white matter damage in the brain. There are currently no disease-modifying treatments, only symptom management.

Does this study mean cerebrolysin doesn't work for brain protection?

Not necessarily. Cerebrolysin has shown neuroprotective effects in other conditions like stroke and Alzheimer's disease. This study specifically looked at cells from CADASIL patients and found the drug only helped in 30% of cases, suggesting the Notch3 mutation may interfere with how cerebrolysin works. Results from one rare genetic disease don't apply to all conditions.

Read the original research

Effects of cerebrolysin administration on oxidative stress-induced apoptosis in lymphocytes from CADASIL patients.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 34(4), 553-6

View on PubMed ↗Publisher’s paper ↗

Citation

Formichi, Patrizia; Radi, Elena; Battisti, Carla; Di Maio, Giuseppe; Dotti, Maria Teresa; Muresanu, Dafin; Federico, Antonio. (2013). Effects of cerebrolysin administration on oxidative stress-induced apoptosis in lymphocytes from CADASIL patients.. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 34(4), 553-6. https://doi.org/10.1007/s10072-012-1174-y